Zydus to commercialize Vascular Endothelial Growth Factor inhibitor Nufymco in US

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2025-12-24 06:00 GMT | Update On 2025-12-24 06:00 GMT

Ahmedabad: Bioeq AG, a Swiss biopharmaceutical company, and Zydus Lifesciences, a life-sciences company with an international presence, have announced that its wholly owned subsidiary, Zydus Lifesciences Global FZE, United Arab Emirates has entered into a strategic partnership with Bioeq, for the licensing, supply and commercialization of Bioeq`s Vascular Endothelial Growth Factor (VEGF) inhibitor NUFYMCO, an interchangeable biosimilar of Lucentis (Ranibizumab) for the U.S. market.

The Biologics License Application (BLA) for NUFYMCO has been approved by U.S. Food and Drug Administration (USFDA) on December 18, 2025.

This transaction marks an expansion of Zydus’ U.S. biosimilar business, following its recent partnership with Formycon AG for a biosimilar of Keytruda (Pembrolizumab).

Read also: Zydus, Formycon join hands to deliver Keytruda biosimilar in US, Canada

Under the terms of this agreement, Bioeq will be responsible for the development, manufacturing, registration and supply of the finished product, while Zydus will be responsible for the commercialisation of NUFYMCO in the U.S. market.

Speaking on the development, Managing Director of Zydus Lifesciences Limited, Dr. Sharvil P. Patel said, “We are happy to collaborate with Bioeq to bring an interchangeable biosimilar to Lucentis (Ranibizumab) in the US market. Through this partnership, we will leverage our combined expertise and resources to accelerate organisational growth while ensuring maximum value to patients through an expanded access to affordable ophthalmology care.”

Dr. Thiemo Schreiber, Vice President Commercial at Bioeq, stated, “We are excited about the regulatory approval of “NUFYMCO by USFDA as an interchangeable biosimilar of Lucentis (Ranibizumab). This latest addition to our portfolio reflects Bioeq’s advanced expertise in developing complex biosimilar medicines for highly regulated markets. Our partnership with Zydus will leverage its extensive distribution network and strong sales and marketing capabilities across the US to broaden treatment options for patients. We are committed to delivering high-quality, affordable therapies and look forward to this collaboration tailored to driving innovation and improving healthcare accessibility.”

The total addressable market opportunity for biosimilar Ranibizumab in the US is approximately US$210 million as per IQVIA MAT Sep 2025.

Read also: Zydus-owned Sentynl's Menkes disease drug NDA resubmission accepted by USFDA

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Zydus to commercialize Vascular Endothelial Growth Factor inhibitor Nufymco in US

Similar News

Quadria Capital sells entire stake in Akums for Rs 311 crore

Codeine syrup smuggling case: Rs 50,000 reward, lookout notice issued against key accused

Banned cough syrup case: Allahabad HC grants interim bail to two brothers

Emcure Pharma gets USFDA EIR for Gujarat facility

State Drug Alert: 141 Medicine Samples Including Mankind's Telmisartan Fail CDSCO Quality Tests in November

Ayush Goes Global: India Introduces Ayush Mark, MAISP to Boost Quality and Credibility

Drug Inspector Shortage Slows Karnataka's Crackdown on Spurious Medicines